Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial

BACKGROUND: Patients with relapsed/refractory B-cell lymphomas have limited treatment options. GERSHWIN is an open-label, single-arm, phase Ib study of obinutuzumab monotherapy in Chinese patients with histologically documented CD20(+) relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Yan, Song, Yuqin, Shen, Zhixiang, Du, Xin, Ji, Wei, Hsu, Wanling, Zhu, Jun, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993131/
https://www.ncbi.nlm.nih.gov/pubmed/29843792
http://dx.doi.org/10.1186/s40880-018-0300-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993131/
https://www.ncbi.nlm.nih.gov/pubmed/29843792
http://dx.doi.org/10.1186/s40880-018-0300-5

Ejemplares similares